Germany is expected to become largest cannabis market in the world; BUY

Synbiotic was one of the first movers in the German cannabinoid market and today is a dominant player with a fully integrated value chain. Based on its footprint in CBD-based wellness & food activities, Synbiotic acquired and integrated two companies in 2021 and 2022 to penetrate the medical cannabis market in Germany. An even stronger kicker is the recreational cannabis market which is expected to reach EUR 3.7bn in size. According to the German Ministry of Health, this could take place in early 2024. It seems reasonable that Synbiotic can achieve a 10% market share in the long run, which is worth some EUR 370m in sales. Investors looking for an attractive investment to participate in the significant growth potential of the German cannabis market cannot bypass Synbiotic. We reiterate to BUY with price target EUR 40.00.

Die vollständige Analyse ist abrufbar unter ResearchHUB

https://www.research-hub.de/disclaimer

 

 

Die SynBiotic Aktie wird zum Zeitpunkt der Veröffentlichung der Nachricht mit einem Minus von -8,09 % und einem Kurs von 10,00EUR auf Tradegate (23. Dezember 2022, 16:47 Uhr) gehandelt.